Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations.
Athyrium advises funds with over $3.7 billion of committed capital.
Secura Bio Announces $145 Million Financing Led By Athyrium Capital Management
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Portola Pharmaceuticals Enters into $125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management
Dermira Enters into Credit Facility with Athyrium Capital Management
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
Amryt Pharma plc announces completion of the acquisition of Aegerion Pharmaceuticals, Inc.
We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Privacy Policy. By closing this message box or continuing to use our website you consent to our use of cookies.
